Evaluation of docetaxel plus estramustine in the treatment of patients with hormone-refractory prostate cancer

International Journal of Urology

Volumn 16, Issue 8, 2009, Pages 687-691

  Matsumoto, Akihiro ^a   Inoue, Atsushi ^a   Yokoi, Satoshi ^a   Nozumi, Kazuyoshi ^a   Miyazaki, Kanetaka ^a   Hosoki, Shigeru ^a   Nagata, Maki ^a   Yamaguchi, Kunio ^a  

^a YOKOHAMA ROSAI HOSPITAL   (Japan)

Author keywords

Docetaxel; Estramustine; Hormone refractory; Intermittent chemotherapy; Prostate cancer

Indexed keywords

DEXAMETHASONE; DIETHYLSTILBESTROL; DOCETAXEL; ESTRAMUSTINE; GONADORELIN DERIVATIVE; GRANULOCYTE COLONY STIMULATING FACTOR; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PAIN; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCORTICOGRAPHY; EVALUATION; FEASIBILITY STUDY; FOLLOW UP; GLEASON SCORE; HUMAN; INTERSTITIAL PNEUMONIA; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PREMEDICATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SIDE EFFECT; STOMACH HEMORRHAGE; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; DRUG THERAPY, COMBINATION; ESTRAMUSTINE; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MIDDLE AGED; ORCHIECTOMY; PROSTATIC NEOPLASMS; TAXOIDS; TREATMENT FAILURE;

EID: 68749083896     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2009.02341.x     Document Type: Article

References (27)

1. Huggins C, Hodges C. Studies on prostate cancer I: the effect of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941 1 : 293 7.
2. Catalona WJ. Management of cancer of the prostate. N. Engl. J. Med. 1994 331 : 996 1003.
3. Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced HRPC. Cancer 1993 71 : 1098 109.
4. Petrylak DP, MacArthue RB, O'Connor J et al. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone-refractory prostate cancer. J. Clin. Oncol. 1999 17 : 958 67.
5. Savarese D, Taplin M, Halabi S et al. A phase II study of docetaxel, estramustine, and low dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of Cancer and Leukemia Group B Trial 9780. Semin. Oncol. 1999 26 : 33 44.
6. Sitki Copur M, Ledakis P, Lynch J et al. Weekly docetaxel and estramustine in patients with hormone-refractory prostate cancer. Semin. Oncol. 2001 28 : 16 21.
7. Bamias A, Bozas G, Antoniou N et al. Prognostic and predictive factors in patients with androgen-independent prostate cancer treated with docetaxel and estramustine: a single institution experience. Eur. Urol. 2007 1974 : 1 10.
8. Nelius T, Klatte T, Yap R et al. A randomized study of docetaxel and dexamethasone with low or high-dose estramustine for patients with advanced hormone-refractory prostate cancer. BJU Int. 2006 98 : 580 5.
9. Hainsworth JD, Meluch AA, Spigel RD et al. Weekly docetaxel/estramustine phosphate in patients with increasing serum prostate-specific antigen levels after primary treatment for prostate cancer: a phase II trial of the Minnie Pearl Cancer Research Network. Clin. Genitourin. Cancer 2006 4 : 287 92.
10. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and predonisone for advanced refractory prostate cancer. N. Engl. J. Med. 2004 351 : 1513 20.
11. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus predonisone or mitoxantrone plus predonisone for advanced prostate cancer. N. Engl. J. Med. 2004 351 : 1502 12.
12. Ringel I, Horwitz SB. Studies with RP 56976 (taxotere): a semisynthetic analog of taxol. J. Natl Cancer Inst. 1991 83 : 288 91.
13. Haldar S, Basu A, Croce CM. Bcl-2 is the guardian of microtubule integrity. Cancer Res. 1997 57 : 229 33.
14. Friedland D, Cohen J, Miller R Jr. et al. A phase II trial of docetaxel (taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2. Semin. Oncol. 1999 26 : 19 23.
15. Laing N, Dahllof B, Hartley-Asp B et al. Interaction of estramustine with tubulin isotypes. Biochemistry 1997 36 : 871 8.
16. Natale RB, Zaretsky SL. Phase I/II trial of estramustine (E) and taxotere (T) in patients with metastatic hormone-refractory prostate cancer (HRPC). Proc. Am. Soc. Clin. Oncol. 1999 18 : 348a (abstr).
17. Sinibaldi VJ, Carducci MA, Moore-Cooper S et al. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate cancer. Cancer 2002 94 : 2457 65.
18. Bubley BJ, Carducci M, Dahut W et al. Eligibility and response guidelines for phase II clinical trial in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J. Clin. Oncol. 1999 17 : 3461 7.
19. Oudard S, Banu E, Beuzeboc P et al. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and predonisone versus mitoxantrone and predonisone in patients with metastatic hormone-refractory prostate cancer. J. Clin. Oncol. 2005 23 : 3343 51.
20. Hainsworth J. Practical aspects of weekly docetaxel docetaxel administration schedules. Oncologist 2004 9 : 538 45.
21. Eymard JC, Priou F, Zannetti A et al. Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer. Ann. Oncol. 2007 18 : 1064 70.
22. Machiels JP, Mazzeo F, Clausse M et al. Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastastic hormone-refractory prostate cancer. J. Clin. Oncol. 2008 26 : 5261 7.
23. Takenaka A, Yamada Y, Kurahasi T et al. Combination chemotherapy with weekly docetaxel and estramustine for hormone refractory prostate cancer in Japanese patients. Int. J. Urol. 2008 15 : 106 9.
24. Petrylak DP, Shelton GB, England-Owen C et al. Response and preliminary survival results of a phase 2 study of docetaxel plus estramustine in patients with androgen-independent prostate cancer. Proc. Am. Soc. Clin. Oncol. 2000 19 : 334a (abstr)
25. Nelius T, Klatte T, de Riese W et al. Impact of PSA flare up in patients with hormone-refractory prostate cancer undergoing chemotherapy. Int. Urol. Nephrol. 2008 40 : 97 104.
26. Olbert PJ, Hegele A, Kraeter P et al. Clinical significance of a prostate-specific antigen flare phenomenon in patients with hormone-refractory prostate cancer receiving docetaxel. Anticancer Drugs 2006 17 : 993 6.
27. Beer TM, Gartotto M, Henner WD et al. Intermittent chemotherapy in metastatic androgen-independent prostate cancer. Br. J. Cancer 2003 89 : 968 70.